Literature DB >> 25142001

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).

Chern Siang Lee1, Margaret Ashton-Key, Sergio Cogliatti, Stephanie Rondeau, Shu-Fang Hsu Schmitz, Michele Ghielmini, Mark S Cragg, Peter Johnson.   

Abstract

Entities:  

Keywords:  Fc receptor; antibody therapy; biomarker; non-hodgkin lymphoma; rituximab

Mesh：

Substances：

Year:  2014        PMID： 25142001     DOI： 10.1111/bjh.13071

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  15 in total

Review 1.  Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Authors:  Pallawi Torka; Mathew Barth; Robert Ferdman; Francisco J Hernandez-Ilizaliturri
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

2.  Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.

Authors:  Ali Roghanian; Mark S Cragg; Björn Frendéus
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

3.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

4.  The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.

Authors:  Laura K Hilton; Jeffrey Tang; Susana Ben-Neriah; Miguel Alcaide; Aixiang Jiang; Bruno M Grande; Christopher K Rushton; Merrill Boyle; Barbara Meissner; David W Scott; Ryan D Morin
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

5.  Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?

Authors:  Venkat R Reddy; Ruth J Pepper; Kavina Shah; Geraldine Cambridge; Scott R Henderson; Christian Klein; Loren Kell; Samuel J Taylor; David A Isenberg; Mark S Cragg; Maria J Leandro
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

Review 6.  Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.

Authors:  Richard J Stopforth; Kirstie L S Cleary; Mark S Cragg
Journal:  J Clin Immunol       Date:  2016-02-27       Impact factor: 8.317

7.  Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.

Authors:  Venkat Reddy; Christian Klein; David A Isenberg; Martin J Glennie; Geraldine Cambridge; Mark S Cragg; Maria J Leandro
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580

8.  Evaluating Anti-CD32b F(ab) Conformation Using Molecular Dynamics and Small-Angle X-Ray Scattering.

Authors:  Emma J Sutton; Richard T Bradshaw; Christian M Orr; Bjorn Frendéus; Gunilla Larsson; Ingrid Teige; Mark S Cragg; Ivo Tews; Jonathan W Essex
Journal:  Biophys J       Date:  2018-07-17       Impact factor: 4.033

9.  Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Venkat Reddy; Geraldine Cambridge; David A Isenberg; Martin J Glennie; Mark S Cragg; Maria Leandro
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

10.  Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Authors:  Sarah E Arthur; Aixiang Jiang; Bruno M Grande; Miguel Alcaide; Razvan Cojocaru; Christopher K Rushton; Anja Mottok; Laura K Hilton; Prince Kumar Lat; Eric Y Zhao; Luka Culibrk; Daisuke Ennishi; Selin Jessa; Lauren Chong; Nicole Thomas; Prasath Pararajalingam; Barbara Meissner; Merrill Boyle; Jordan Davidson; Kevin R Bushell; Daniel Lai; Pedro Farinha; Graham W Slack; Gregg B Morin; Sohrab Shah; Dipankar Sen; Steven J M Jones; Andrew J Mungall; Randy D Gascoyne; Timothy E Audas; Peter Unrau; Marco A Marra; Joseph M Connors; Christian Steidl; David W Scott; Ryan D Morin
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.